Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.49 |
| ▸ | CA2 | P00918 | 10/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11862063 | 0.82 | CA1 (0.65) | CA1CA2CA12CA9ACHE | |
| SCHEMBL9177535 | 0.81 | CA1 (0.63) | CA1CA2CA12CA9MAPT | |
| SCHEMBL30278496 | 0.80 | CA1 (0.57) | CA1CA2CA12CA9ACHE | |
| SCHEMBL3829119 | 0.78 | CA1 (0.57) | CA1CA2CA12CA9MMP2 | |
| SCHEMBL3819564 | 0.78 | CA1 (0.53) | CA1CA2CA12CA9ACHE | |
| SCHEMBL27643285 | 0.76 | CA1 (0.55) | CA1CA2CA12CA9ACHE | |
| SCHEMBL3821884 | 0.76 | CA1 (0.57) | CA1CA2CA12CA9ACHE | |
| SCHEMBL7605430 | 0.74 | CA1 (0.67) | CA1CA2CA12CA9ACHE | |
| SCHEMBL5931094 | 0.74 | EGFR (0.55) | CA1CA2CA12CA9MAPT | |
| SCHEMBL26571620 | 0.72 | CA1 (0.58) | CA1CA2CA12CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20170340646-A1 | Methods and Compositions for Decreasing Gastric Emptying | PURDUE PHARMA L.P. | 2017-11-30 | — | — | US | disclosed |
| US-9763955-B2 | Methods and compositions for decreasing gastric emptying | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160243129-A1 | Methods and Compositions for Decreasing Gastric Emptying | PURDUE PHARMA L.P. | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243129-A1 | Methods and Compositions for Decreasing Gastric Emptying | GIPR, SLC10A2, CCKBR | CA1 543/4885CA2 172/4885CA12 1956/4885 |
| US-20170340646-A1 | Methods and Compositions for Decreasing Gastric Emptying | GIPR, SLC10A2, CCKBR | CA1 543/4885CA2 172/4885CA12 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.